Skip to search formSkip to main contentSkip to account menu

amrubicin

Known as: (+)-(7S,9S)-9-Acetyl-9-amino-7-((2-deoxy-beta-D-erythro-pentopyranosyl)oxy)- 6,11-dihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione 
A synthetic 9-amino-anthracycline with antineoplastic activity. Amrubicin intercalates into DNA and inhibits the activity of topoisomerase II… 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (2)

AnthracyclinesAntineoplastic Agents
NCIt Antineoplastic Agent Terminology

Narrower (2)

SM 5887amrubicin hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2014
Highly Cited
2014
Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer.
PURPOSE Amrubicin, a third-generation anthracycline and potent topoisomerase II inhibitor, showed promising activity in small… 
Highly Cited
2014
Highly Cited
2014
Phase III study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer: JCOG 0509.
PURPOSE This randomized phase III trial was conducted to confirm noninferiority of amrubicin plus cisplatin (AP) compared with… 
Highly Cited
2011
Highly Cited
2011
Randomized phase II trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy.
PURPOSE This phase II study evaluated the safety and efficacy of single-agent amrubicin versus topotecan in patients with small… 
Highly Cited
2011
Highly Cited
2011
Randomized phase III trial of amrubicin versus topotecan (Topo) as second-line treatment for small cell lung cancer (SCLC).
7000 Background: Amrubicin (AMR), a 3rd-generation anthracycline and potent topoisomerase II inhibitor, has shown promising… 
Review
2007
Review
2007
Amrubicin for non-small-cell lung cancer and small-cell lung cancer
SummaryAmrubicin is a totally synthetic anthracycline anticancer drug and a potent topoisomerase II inhibitor. Recently… 
2006
2006
Phase II trial of amrubicin in patients with previously treated small cell lung cancer (SCLC).
7061 Background: Amrubicin, a totally synthetic 9-amino-anthracycline, has been shown to have excellent antitumor activity as a… 
Review
2001
Review
2001
New drugs for chemotherapy-naive patients with extensive-disease small cell lung cancer.
Highly Cited
1998
Highly Cited
1998
Cytotoxicity of Amrubicin, a Novel 9‐Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells
Amrubicin, a completely synthetic 9‐aminoanthracycline derivative, was previously shown to have potent antitumor activities… 
Highly Cited
1998
Highly Cited
1998
A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex
Amrubicin is a novel, completely synthetic 9‐aminoanthracycline derivative. Amrubicin and its C‐13 alcohol metabolite… 
1998
1998
In vivo Efficacy and Tumor‐selective Metabolism of Amrubicin to Its Active Metabolite
The tissue distribution of a novel antitumor anthracycline antibiotic, amrubicin, was studied using seven human tumor xenografts… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)